One-Time gene shot aims to tame rare enzyme disorder

NCT ID NCT06818838

First seen Jan 23, 2026 · Last updated May 14, 2026 · Updated 12 times

Summary

This early-phase trial tests a single injection of gene therapy (LY-M001) in 12 adults with Gaucher disease type 1, a genetic condition causing enzyme deficiency and organ damage. The therapy delivers a working gene to the liver to produce the missing enzyme. The main goals are safety and checking if the treatment can improve enzyme levels and reduce liver and spleen swelling.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangzhou First People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hematology Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Tianjin, Tianjin Municipality, 300011, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanxi Bethune Hospital

    RECRUITING

    Taiyuan, Shanxi, 030000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.